We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 | 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
From Apr 2022 to Apr 2024
By Pierre Bertrand
Sanofi shares fell in early Wednesday trading after the company discontinued its global clinical development program for breast-cancer drug amcenestrant.
At 0733 GMT, shares of the French pharmaceutical company traded 4.1% lower to EUR83.01.
An independent data-monitoring committee found that amcenestrant, which targets a type of advanced or metastatic breast cancer, didn't satisfy the requirements for continued study and recommended stopping the trial, Sanofi said.
The decision to shelve the treatment program was based on the interim review of its Phase 3 Ameera-5 trial. All other trials involving the drug, including its AMEERA-6 early-stage breast cancer trial, will be discontinued, Sanofi said.
The end of amcenestrant's development program comes after the drug's Phase 2 clinical trial failed in March.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
August 17, 2022 04:00 ET (08:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
